Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors
AssigneeAcurastem Incorporated
InventorsJustin K. ICHIDA, Matthew STREMLAU, Hongyan ZHOU
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating viral infections including COVID-19 and compositions with a combination of (i) an inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) and (ii) an inhibitor of transmembrane serine proteinase 2 (TMPRSS-2).
Claims19
A method for treating a subject having a viral infection comprising administering to the subject an effective amount of (i) a PIKfyve inhibitor and (ii) a TMPRSS-2 inhibitor, wherein the combination of the PIKfyve inhibitor and TMPRSS-2 inhibitor has a lower half-maximal inhibitory concentration for the viral infection than either the PIKfyve inhibitor or the TMPRSS-2 inhibitor alone.
8-9. (canceled)
A method for treating a subject having a viral infection comprising administering to the subject an effective amount of (i) (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol, or a pharmaceutically acceptable salt thereof;
- and (ii) nafamostat, or a pharmaceutically acceptable salt thereof, wherein the combination of (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol and nafamostat has a lower half-maximal inhibitory concentration for the viral infection than either the (S)-2-methoxy-1-(4-morpholino-6-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrimidin-2-yl)ethan-1-ol or nafamostat alone.
A pharmaceutical composition comprising a PIKfyve inhibitor and TMPRSS-2 inhibitor.
Dependencies are inferred from the claim text.